The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Task variability/correlations decrease independently of mean task activity removal step in fMRI data. by Takuya Ito (57473)

HRV parameters at different time points. by Shiying Liu (1569478)

Subjects:

Least Square Means (LSM) plots for factors impacting infected area on plates. by Alla Bezhentseva (12481585)

“…C–LSM plot of infected area by the interaction of Layers and Volume.</p>…”

Cooperative populations have a rescue probability comparable to that of non-cooperative ones only when their growth rate is significantly higher. by Yaron Goldberg (10164674)

AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner. by Matthew Drill (22258391)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

List of acronyms, meanings and units of all measurements or calculations on Atlantic sea scallop, <i>Placopecten magellanicus</i>, during an 8-week exposure to CO₂ enric... by Emilien Pousse (14664318)

Subjects:

Divergence from transmitted/founder (TF) virus increases during ART-naïve infection and decreases on treatment. by Kelsie Brooks (8928044)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: